MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company: Dear OneMedNet Shareholders, Partners, and Family, 2025 has been a year of focus for OneMedNet – focus on our platform, focus on our people, ...

Core Insights - OneMedNet Corporation has demonstrated significant engagement and commercial traction at the RSNA Annual Meeting, indicating strong interest from hospitals, imaging centers, and life sciences innovators in its iRWD™ platform powered by Palantir Foundry [1][2][5] Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data (RWD) networks, leveraging over 2,130 healthcare sites to deliver insights that drive innovation in healthcare [6] - The company focuses on providing high-quality, multimodal datasets that support healthcare providers and life sciences organizations in research and product development [5][6] Market Validation - The RSNA 2025 event validated OneMedNet's strategy amid rising demand for regulatory-grade RWD, with healthcare providers expressing a strong interest in utilizing their clinical data assets [2][3] - Life sciences companies and AI developers showed keen interest in the next-generation iRWD™ platform, highlighting its capabilities in providing large-scale, high-fidelity datasets and AI-enabled cohort discovery [4][5] Strategic Partnerships - Healthcare providers are looking for reliable and low-effort ways to engage in healthcare innovation and research, while life sciences organizations require scalable datasets to accelerate product development [5] - OneMedNet's efficient deployment model and opportunities for compliant data sharing were noted as key advantages for potential partners [3][5]

Core Insights - OneMedNet Corporation has received strong validation for its redesigned data exploration and cohort-building platform from customers and prospects at ISPOR Europe, showcasing its commercial relevance and competitive differentiation [2][3] - The platform, built on Palantir Foundry and AIP, allows research teams to determine cohort feasibility in minutes instead of weeks, enhancing accuracy and efficiency [3][4] Company Overview - OneMedNet operates the largest global live, regulatory-grade AI-ready Real-World Data (RWD) network, encompassing over 2,130 provider sites, 47+ million unique patient lives, and 186+ million clinical exams and images [2][4] - The company aims to revolutionize the use of Real-World Data, providing insights that drive innovation in drug development, medical devices, and AI applications [4][5] Technological Advancements - Key advancements of the new platform include significantly faster cohort feasibility, AI-driven natural-language search for complex discovery tasks, and real-time availability of longitudinal insights [7] - The platform supports subscription workflows, which is expected to contribute to recurring-revenue growth for the company [7]

Core Insights - OneMedNet Corporation has significantly expanded its iRWD™ network, enhancing its position as one of the largest live Real-World Data networks globally [1][2] - The company is experiencing momentum in its subscription model, which is crucial for capturing a share of the $60 billion Real-World Evidence market [2][3] Company Expansion - Approximately 380 new provider sites have been added, bringing the total to over 2,130, representing a 22% increase in network scale [6] - Unique de-identified patient records have increased by 13 million, totaling over 47 million, which is a 38% growth [6] - Clinical exams and images have expanded by 50 million, now exceeding 186 million, marking a 37% increase [6] Market Position - OneMedNet's subscription offerings are attracting pharmaceutical, life-science, and AI customers, leading to a virtuous cycle of increased commitments from existing subscribers and new long-term partnerships [2][3] - The company aims to leverage its extensive network to provide precise, diverse, and longitudinal cohorts, enhancing the value of its data feeds [2][3]

Core Insights - OneMedNet Corporation reported significant financial and operational progress in Q3 2025, highlighting a strong sales pipeline and increased demand for its AI-powered Real-World Data solutions [1][4]. Financial Highlights - Bookings reached $1.1 million in Q3 2025, representing an 815% increase compared to Q3 2024 [8]. - The company successfully completed an additional $0.5 million private placement of common stock, enhancing its strategic investment capabilities [8]. - OneMedNet improved its balance sheet by reducing total liabilities by $1.9 million in Q3, with a total reduction of $14.3 million year-to-date [8]. Operational Highlights - The integration of Palantir's AI Platform commenced in September 2025, enhancing the iRWD™ network with capabilities such as faster data discovery, AI-driven de-identification, and multimodal data integration [8]. - The rollout of a SaaS subscription model was announced, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [8]. - The company emphasized its focus on strategic opportunities to deliver long-term value, resulting in a 4.5X increase in inbound demand and larger deal sizes [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40386 ONEMEDNET CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 86-2076743 (State or other juris ...

Core Insights - OneMedNet Corporation is set to showcase its next-generation iRWD™ platform at ISPOR Europe, which leverages the Palantir Technologies Foundry ecosystem to provide secure, regulatory-grade real-world data (RWD) through advanced AI analytics [1][3] - The company has introduced a recurring revenue model that enhances customer access to high-value RWD, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [2][7] - The healthcare sector is projected to present an estimated US$868 billion opportunity by 2030, with a significant challenge being the acquisition of high-quality, de-identified clinical multimodal data [3] Company Developments - OneMedNet's iRWD™ platform is designed to revolutionize the access and operationalization of real-world data from over 1,750 healthcare sites, providing insights that can drive innovation in drug development and patient care [4] - The platform's Live Data Feeds offer real-time streams of de-identified clinical data, while the AI-Driven Conversational Search allows users to query complex datasets using natural language, enhancing data accessibility and reducing technical barriers [7] Market Context - The AI-enabled market within healthcare is at a transformative inflection point, with responsible access to healthcare data being a key barrier to unlocking its full potential [3] - OneMedNet's collaboration with Palantir is expected to enhance its capabilities in delivering regulatory-grade, multimodal RWD with improved speed, consistency, and security [3]

Core Insights - OneMedNet Corporation has been selected by mlHealth360 as its Real-World Data provider, marking a significant milestone in the expansion of OneMedNet's subscription-based business model [1][2][3] Company Overview - OneMedNet is a leader in AI-powered Real-World Data (RWD), utilizing data from over 1,750 healthcare provider sites and 131 million+ clinical studies to support healthcare innovation [1][4] - The company’s iRWD™ platform provides regulatory-grade, de-identified imaging and clinical data, which is crucial for AI model development and validation [2][4] Partnership Details - The multi-year agreement with mlHealth360 allows continuous access to curated X-Ray and CT datasets, enhancing mlHealth360's capabilities in medical imaging [2][3] - The collaboration aims to improve patient care by providing high-quality medical imaging data, which is essential for advancing AI model development [3][6] Market Demand - There is a growing market demand for high-quality, multimodal Real-World Data that supports model training and regulatory-grade validation, highlighting the importance of partnerships with AI and analytics companies [3][4]

Company Movements - Spruce Biosciences, Inc. experienced a monumental surge, with its price jumping to $136.81, marking a 1451% increase due to the FDA granting Breakthrough Therapy Designation for its tralesinidase alfa enzyme replacement therapy for treating Sanfilippo Syndrome Type B [1][7] - OneMedNet Corporation Warrants saw its price increase by 233.17% to $0.19, related to a strategic partnership with Palantir Technologies to enhance its healthcare AI and data analytics capabilities [2][7] - OneMedNet Corporation also made notable gains, with its price escalating by 184.88% to $2.93, driven by investor optimism around its technology and the partnership with Palantir Technologies [3][7] - Society Pass Incorporated experienced a 146.18% increase in its price to $3.47, following an analyst upgrade based on the company's robust second-quarter performance and positive future outlook [4][7] - Argo Blockchain plc saw its price rise by 106.89% to $0.86, despite uncertainty over its financial future, linked to ongoing negotiations regarding a senior secured loan crucial for its recapitalization plan [5][7] Market Dynamics - The significant price movements of these companies underscore the diverse factors at play in the financial markets, including technological innovations, clinical advancements, and strategic corporate actions [6][7]

Company Developments - Advanced Micro Devices (NASDAQ:AMD) shares surged over 27% following a landmark agreement with OpenAI to deploy up to 6 gigawatts of AMD Instinct GPU power for AI infrastructure [2][3] - The initial phase includes a rollout of 1 gigawatt of AMD Instinct MI450 GPUs in the second half of 2026, with plans for further expansions across multiple generations of AMD's data center chips [2] Market Movements - Spruce Biosciences, Inc. (NASDAQ:SPRB) shares increased by 316% after receiving U.S. FDA breakthrough therapy designation for its enzyme replacement therapy for Sanfilippo Syndrome Type B [9] - OneMedNet Corporation (NASDAQ:ONMD) shares surged 143% after selecting Palantir Technologies to enhance its healthcare AI and real-world data analytics operations [9] - Society Pass Incorporated (NASDAQ:SOPA) shares rose by 113% [9] - Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) shares fell 58% [9] - Skye Bioscience, Inc. (NASDAQ:SKYE) shares dropped 54% after failing to meet primary endpoint in a study [9] - Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) shares decreased by 28% following a $25 million public offering announcement [9] Commodity Updates - Oil prices increased by 0.7% to $61.28, while gold rose by 1.8% to $3,977.90 [6] - Silver traded up 1.1% to $48.485, whereas copper fell by 1.4% to $5.0365 [6]